🇺🇸 FDA

Intelligence · Patents

Recently granted patents

New US pharmaceutical patent grants from the past 12 months — competitive surveillance for BD and IP teams.

Patents
632

Quick answer

632 pharmaceutical patents in our USPTO index were granted within the past year. Browse by grant date with links to applicant company portfolios and related drug profiles.

  1. US 12343380

    Expansion of TILs utilizing AKT pathways inhibitors

    Iovance Biotherapeutics, Inc. · Granted Tue Jul 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 26 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12343432

    Encapsulated probiotic

    UNITED ARAB EMIRATES UNIVERSITY · Granted Tue Jul 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 26 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12343350

    Istaroxime-containing intravenous formulation for the treatment of acute heart failure (AHF)

    Windtree Therapeutics, Inc. · Granted Tue Jul 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 26 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 12343324

    Dihydromyricetin hot melt extrusion formulations and methods for forming them

    THE TRUSTEES OF PRINCETON UNIVERSITY · Granted Tue Jul 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 26 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 12344585

    Crystalline salts of a plasma kallikrein inhibitor

    BioCryst Pharmaceuticals, Inc. · Granted Tue Jul 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 26 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 12344654

    Mage A4 T cell receptors

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Jul 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 26 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 12336995

    Combination therapies

    Mirati Therapeutics, Inc. · Granted Tue Jun 24 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 19 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 12336973

    Cancer therapeutic compositions and methods targeting DNAse1L3

    Providence Health & Services—Oregon · Granted Tue Jun 24 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 19 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 12338437

    OPA1 antisense oligomers for treatment of conditions and diseases

    STOKE THERAPEUTICS, INC. · Granted Tue Jun 24 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 19 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 12338450

    Gene therapy constructs for treating Wilson disease

    Ultragenyx Pharmaceutical Inc. · Granted Tue Jun 24 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 19 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 12338274

    Anti-VEGF protein compositions and methods for producing the same

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Jun 24 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 19 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 12337019

    Vehicles for applying bacteria to skin, scalp, and hair

    Northwestern University · Granted Tue Jun 24 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 19 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 12336980

    Dosing regimen for a selective S1P1 receptor agonist

    VANDA PHARMACEUTICALS INC. · Granted Tue Jun 24 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 19 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 12338438

    Conjugated oligonucleotide compounds, methods of making and uses thereof

    E-Therapeutics PLC · Granted Tue Jun 24 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 19 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 12338218

    Crystal form of benzimidazole-2-one compound, solvate thereof, crystal form of solvate thereof, and preparation method thereof

    Medshine Discovery Inc. · Granted Tue Jun 24 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 19 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 12336983

    Inhibition of crystal growth of roflumilast

    ARCUTIS BIOTHERAPEUTICS, INC. · Granted Tue Jun 24 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 19 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 12336835

    Neuromodulation to target glucose transporter and/or incretin pathways

    GE Precision Healthcare LLC · Granted Tue Jun 24 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 19 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 12337033

    Encapsulated glycolipid antigens for treatment of neoplastic diseases

    EnGeneIC Molecular Delivery Pty Ltd · Granted Tue Jun 24 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 19 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 12336985

    Methods for shrinking pituitary tumors

    Corcept Therapeutics Incorporated · Granted Tue Jun 24 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 19 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 12338219

    Antimalarial agents

    MSD R&D (China) Co. Ltd. · Granted Tue Jun 24 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 19 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 12338231

    N-heterocycle substituted tryptamine derivatives and methods of using

    Enveric Biosciences Canada Inc. · Granted Tue Jun 24 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 19 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 12336974

    Methods and compositions for preventing and treating auditory dysfunctions

    United States Government as represented by the Department of Veterans Affairs · Granted Tue Jun 24 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 19 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 12338199

    Bis-octahydrophenanthrene carboxamides and protein conjugates thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Jun 24 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 19 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 12336982

    Compositions and methods of modulating short-chain dehydrogenase activity

    The Board of Regents of the University of Texas System · Granted Tue Jun 24 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 19 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 12336976

    Glutaminase inhibitor therapy

    The Board of Regents of the University of Texas System · Granted Tue Jun 24 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 19 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 12338459

    DNA-chimeric antigen receptor T cells for immunotherapy

    ARIZONA BOARD OF REGENTS FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY · Granted Tue Jun 24 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 19 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 12337017

    Microbiota transfer therapy for Pitt Hopkins Syndrome

    ARIZONA BOARD OF REGENTS FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY · Granted Tue Jun 24 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 19 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 12338439

    Factor XII (hageman factor) (F12), kallikrein B, plasma (fletcher factor) 1 (KLKB1), and kininogen 1 (KNG1) iRNA compositions and methods of use thereof

    Alnylam Pharmaceuticals, Inc. · Granted Tue Jun 24 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 19 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 12338242

    TYK2 inhibitors and uses thereof

    Takeda Pharmaceutical Company Limited · Granted Tue Jun 24 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 19 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 12337020

    Bacteriophage compositions

    Takeda Pharmaceutical Company Limited · Granted Tue Jun 24 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 19 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 12336990

    Treatment of prostate cancer

    Takeda Pharmaceutical Company Limited · Granted Tue Jun 24 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 19 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 12338269

    IL-2 superagonists in combination with anti-PD-1 antibodies

    Medicenna Therapeutics Inc. · Granted Tue Jun 24 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 19 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 12338249

    Crystalline forms of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N′-methoxyurea

    Takeda Pharmaceutical Company Limited · Granted Tue Jun 24 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 19 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 12337199

    Stable antibody formulation

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Jun 24 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 19 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 12331130

    DDR1 antibodies and uses thereof

    The Board of Regents of the University of Texas System · Granted Tue Jun 17 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 12 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 12329825

    Muscle targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of use thereof to induce exon skipping of exon 44 of dystrophin in a subject

    Dyne Therapeutics, Inc. · Granted Tue Jun 17 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 12 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 12329772

    Methods and compositions for administration of iron

    American Regent, Inc. · Granted Tue Jun 17 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 12 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 12329824

    Muscle targeting complexes and uses thereof for treating dystrophinopathies

    Dyne Therapeutics, Inc. · Granted Tue Jun 17 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 12 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 12331099

    VEGF antagonist formulations suitable for intravitreal administration

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Jun 17 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 12 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 12329751

    Topical roflumilast formulation having antifungal properties

    ARCUTIS BIOTHERAPEUTICS, INC. · Granted Tue Jun 17 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 12 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 12331124

    ALK2 antibodies and methods of use thereof

    Keros Therapeutics, Inc. · Granted Tue Jun 17 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 12 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 12331132

    Multispecific polypeptide constructs having constrained CD3 binding and related methods and uses

    Inhibrx Biosciences, Inc. · Granted Tue Jun 17 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 12 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 12331057

    Modulators of alpha-1 antitrypsin

    Vertex Pharmaceuticals Incorporated · Granted Tue Jun 17 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 12 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 12331328

    CRISPR/Cas9-mediated exon-skipping approach for USH2A-associated usher syndrome

    Editas Medicine, Inc. · Granted Tue Jun 17 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 12 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 12329805

    Dosage forms of tissue kallikrein 1

    DiaMedica Inc. · Granted Tue Jun 17 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 12 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 12329784

    Gut microbiota and treatment of cancer

    SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · Granted Tue Jun 17 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 12 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 12329747

    Use of lipophilic beta-lactam antibiotics and carboxylate esters for the treatment of bacterial infections within citrus and other plant species

    Board of Regents of the Nevada System of Higher Education on behalf of Nevada State College · Granted Tue Jun 17 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 12 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 12331056

    SHP2 phosphatase inhibitors and methods of use thereof

    Relay Therapeutics, Inc. · Granted Tue Jun 17 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 12 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How recent are these patent grants?

This hub lists published patents with a grant date within the last 365 days, ordered newest first.

Which patent classes are included?

We index USPTO PatentsView records with pharmaceutical CPC classifications A61K and A61P linked to tracked assignee companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.